Carl R. Walkley

Carl R. Walkley

Auto-generated profile, based on publicly available information

Carl R. Walkley

Centre for Innate Immunity and Infectious Disease, Hudson Institute of Medical Research 1 , Clayton, Victoria, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2011 in Nature
Verified
Journal Article
Closed access
PDF file
ESErgün Sahin
Ergün Sahin
SCSimona Colla
Simona Colla
Marc LiesaMarc Liesa
Marc Liesa
JMJavid Moslehi
Javid Moslehi
Florian MullerFlorian Muller
Florian Muller
RDRonald A. Depinho
Ronald A. Depinho

21 June 2007 in Nature
Verified
Journal Article
Closed access
PDF file
TNTrista E. North
Trista E. North
WGWolfram Goessling
Wolfram Goessling
CWCarl R. Walkley
Carl R. Walkley
CLClaudia Lengerke
Claudia Lengerke
KKKamden R. Kopani
Kamden R. Kopani
LZLeonard I. Zon
Leonard I. Zon

4 September 2015 in Science
Verified
Journal Article
Closed access
PDF file
BLBrian J. Liddicoat
Brian J. Liddicoat
RPRobert Piskol
Robert Piskol
ACAlistair M. Chalk
Alistair M. Chalk
GRGokul Ramaswami
Gokul Ramaswami
MHMiyoko Higuchi
Miyoko Higuchi
CWCarl R. Walkley
Carl R. Walkley
RNA editing helps identify cellular RNAs: Adenosine bases in messenger RNA (mRNAs) can be enzymatically modified and changed into inosine bases. This RNA “editing” is mediated by adenosine deaminase acting on RNA (ADAR) enzymes. Liddicoat et al. show that the in vivo targets of the principal editing enzyme, ADAR1, are long double-stranded RNA (dsRNA) structures in noncoding portions of cellular mRNAs. ADAR1-directed editing of these cellular targets is critical to avoid activation of an immune response to dsRNA in the cytoplasm, because dsRNA is also a marker of viral infection. Science , this issue p. 1115

12 October 2017 in Nature
Verified
Journal Article
Closed access
PDF file
GCGTEx Consortium
GTEx Consortium
MTMeng How Tan
Meng How Tan
QLQin Li
Qin Li
RSRaghuvaran Shanmugam
Raghuvaran Shanmugam
RPRobert Piskol
Robert Piskol
JLJin Billy Li
Jin Billy Li

1 June 2007 in Cell
Verified
Journal Article
Closed access
CWCarl R. Walkley
Carl R. Walkley
GOGemma Haines Olsen
Gemma Haines Olsen
SDSebastian Dworkin
Sebastian Dworkin
SFStewart A. Fabb
Stewart A. Fabb
JSJeremy Swann
Jeremy Swann
LPLouise E. Purton
Louise E. Purton

7 December 2008 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JHJochen C Hartner
Jochen C Hartner
CWCarl R Walkley
Carl R Walkley
JLJun Lu
Jun Lu
SOStuart H Orkin
Stuart H Orkin
ADAR1 is an adenosine deaminase that acts on double-stranded RNA. Orkin and colleagues show that ADAR1 protects hematopoietic stem cells from interferon-induced insult and is needed to maintain long-term hematopoiesis. The deaminase ADAR1 edits adenosines in nuclear transcripts of nervous tissue and is required in the fetal liver of the developing mouse embryo. Here we show by inducible gene disruption in mice that ADAR1 is essential for maintenance of both fetal and adult hematopoietic stem cells. Loss of ADAR1 in hematopoietic stem cells led to global upregulation of type I and II interferon–inducible transcripts and rapid apoptosis. Our findings identify ADAR1 as an essential regulator of hematopoietic stem cell maintenance and suppressor of interferon signaling that may protect organisms from the deleterious effects of interferon activation associated with many pathological processes, including chronic inflammation, autoimmune disorders and cancer.